Driven by Solutions
Solve the complex
During the lead phase, we refine functional properties to optimize clinical success, boost efficiency, and ensure scalability. By harnessing intelligent data integration and advanced analytics, we systematically evaluate candidates for efficacy, binding strength, and key functional traits. Our data-driven approach optimizes therapeutic potential at each stage, which is aimed at reducing development time and costs. By minimizing traditional design, test, and update cycles—now done in parallel and at a glance—we shorten timelines while focusing on precise selection of high-efficacy candidates and enhancing IP value.
Technology built specifically for the clinical race.
Reduce cycles with multi-parametric analysis for faster, more efficient results.
Take out the guesswork. Discover more insights and hidden characteristics faster.
Accelerate antibody discovery and development timelines by up to 300%
Traditional methodsAverage 3-6 years*
Traditional methods
Average 3-6 years*
Fusion of in vitro, in vivo, in silico servicesAverage 1-3 years*
Fusion of lab and AI services
Average 1-3 years*
*Average approximation of timeline advantage.Projects may vary.
*Average approximation of timeline advantage.
Projects may vary.
See it in action
Applications enhanced by a range of additional functional tools
Epitope Mapping
- High-throughput
- No need for physical materials
- Integrated structural modeling capabilities
- All target types
- Get insights earlier in the discovery & development process
Insight in predicted epitope region and interacting antigen residues through an interactive dashboard.
Immunogenicity Screening
- High-throughput, versatile use
- All antibody formats and proteins
- Compare reference input to a therapeutic antibody and protein database for insights guiding humanization and engineering
- Early identification of potential safety issues
Gain a comprehensive comparison with a therapeutic reference and in-depth analysis of immunogenic hotspots.
pH Optimization
- In silico mAb engineering targeting preferential binding at pH of tumor micro environment
- Includes in silico structural modeling, epitope prediction and identification of interacting residues
- Proven
- Reduce timelines
Ab with newly engineered preferential binding to cell surface expressed target under condition A (TCA) compared to the parental Ab (public Ab)
Unlocking success with data insights, diversity, and risk mitigation
By combining comprehensive data insights, diverse approaches, and strategic risk reduction, we accelerate breakthroughs aimed at precise, successful outcomes.
LENSai Leads
Innovate without limits: choose your path
Access to our cutting-edge technology is designed with flexibility in mind, offering multiple formats tailored to your unique requirements. Whether you’re seeking seamless integration, full-scale deployment, or a customized solution, we have an option to elevate your research.
BioIntelligence Suite Fee-for-Service
Customized solutions allowing clients to leverage expert capabilities and advanced technologies for their specific research needs.
Strategic
Partnership
Strategic partnerships in antibody discovery grant access to all technologies, accelerating innovation and driving shared success through combined expertise and resources.
BioIntelligence Cloud SaaS
Early access to LENSai SaaS model empowers users to leverage cutting-edge tools and features ahead of the competition, enhancing productivity and innovation.
Scalable
API Access
API access streamlines integration, allowing seamless connection to powerful tools and data for enhanced research efficiency.
Seamless continuum: merging wet lab power with generative AI for clinical breakthroughs
Unlock unparalleled efficiency and optimization with our customized end-to-end solution, seamlessly integrating in vitro, in vivo, and in silico through a combined fee-for-service or partnership offering with IPA (our parent company). This comprehensive strategy accelerates your decision-making and propels therapeutic approaches from discovery to the clinic faster than ever. Trusted by 19 of the top 20 pharma companies, our expertise and service depth offering is your key to achieving clinical success with precision and speed.
See IPAPowered by:
BioStrand proprietary data integration intelligence
LENSai platform is hosted on AWS
Vector search intelligence is at the core of LENSai platform, seamlessly integrated with the InterSystems IRIS data platform to deliver precise, scalable solutions that accelerate antibody discovery, enhance accuracy, and increase candidate diversity.